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Renal impairment associated
with non-steroidal
anti-inflammatory drugs
SIR, The study by Unsworth et al' would appear to have
methodological deficiencies which limit both its conclu-
sions and its applicability to rheumatic patients taking non-
steroidal anti-inflammatory drugs (NSAIDs). These
include the reason for choosing to discontinue the medica-
tion in a particular individual; the lack of information
about the reason for admission of the patients, and
particularly their state of hydration, and stability of renal
function compared with previous estimations; the variable
time before discharge or reintroduction of NSAIDs, which
results in distortion of the slopes in Fig. 2, in which the
serum creatinine and urea graphs include results of
patients 23-27 who are not referred to anywhere else in the
article; the reliance on creatinine clearance as a measure of
renal function, with its inherent inaccuracies (two valida-
tions with CrEDTA out of 22 estimations are not sufficient
reassurance); and the lack of randomisation.
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SIR. Perhaps we did not clearly explain some of the points
that Dr Gow raises in his letter: NSAID ingestion is
increasingly recognised as a cause of renal failure; our
patients show reversible renal suppression. We feel that
this observation is applicable to all patients taking these
drugs. Our patients were admitted sequentially from a
waiting list for treatment or assessment of their rheuma-
tological condition(s), and this is of no relevance to the
ensuing discussion. They volunteered to stop NSAIDs to
assess the effect of withdrawal of these drugs on renal
function. That their length of stay and tolerance to NSAID
removal would be variable is obvious. We clearly state
that, unless described in the text, all recognised pre-
dispositions to NSAID nephrotoxicity had been excluded,
and dehydration is referenced in this context. The in-
clusion of patients 23-27 is an illustrative error and has no
bearing on this or previous discussions; they form part of a
different study and our statistics do not include these data.
Creatinine clearances remain the best method commonly
available for the measurement of renal function. The fact
that they change significantly and consistently is the
message that we have tried to get across. Our aim in
publishing this small study, which poses more questions
than it answers, is to alert NSAID prescribers to possibly
common side effects, and we feel that renal monitoring
should be considered in all patients receiving these drugs.
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Rheumatoid factor in patients
with systemic lupus
erythematosus
SIR, In the report by Helin et al in the Annals' the authors
suggest that rheumatoid factor (RF) protects against
nephropathy in patients with systemic lupus erythematosus
(SLE).
We have reviewed our series of 78 patients with SLE
fulfilling the criteria of the above report for evaluating
nephropathy and assaying RF. The Waaler-Rose sensitised
sheep cell agglutination test was used to measure RF, with
titres equal or greater than 1/64 considered positive. Both
groups with and without renal disease were comparable for
age and sex. A renal biopsy was performed in 38 out of 40
patients with nephropathy. The results are shown in Table
1.
Table 1 Rheumatoid factor and nephropathy in SLE*
With Without Total
nephropathy nephropathy
RF(+) 4 5 9
RF (-) 36 33 69
Total 40 38 78
% RF (+) 10 13-1 11-5
*Numbers of patients are given.
Our results differ from those obtained by Helin et al,'
Davis and Bollet, and Hill et al,3 and agree with those
obtained by Kantor et aP and Baldwin et al.5 We found no
significant difference between the percentages of positive
RF in the groups with or without nephropathy. In addition,
in the four cases with renal disease and RF (+) the renal
biopsy specimens showed severe morphological lesions
(three cases of diffuse proliferative glomerulonephritis and
one case of membranous glomerulonephritis).
The discrepancy between these studies does not permit
definite conclusions to be reached about the role of RF in
the aetiopathogenesis of SLE nephropathy.
'Servicio de Medicina Interna ROSA MORENO PINILLOS'
and 2Secci6n de JOAN MIQUEL NOLLA SOLE2
Reumatologia XAVIER JUANOLA ROURA2
Hospital de Bellvitge, VISITACION PAC FERRAZ
Universidad de Barcelona, ANTONIO VIDALLER PALACIN
L'Hospitalet de Llobregat, ISABEL MOGA SAMPERE
Barcelona
 group.bmj.com on July 6, 2011 - Published by ard.bmj.comDownloaded from 
878 Correspondence
References
I Helin H. Korpela M. Mustonen J. Pasternac
factor in rheumatoid airthritis associated ren
lupus nephritis. Annii Rhelutm Dis 1986: 45:
2 Davis J S. Bollet A J. Complement lesels. r
and renal disease in svstemic lupus crxth
Arthritis Rheuwn 1966: 9: 499-500.
3 Hill G S. Hinglais N. Tron F. Bach J-F
erythematosus. Morphologic correlations sM
and clinical data at the timc of biopsv. AIn
61-79.
4 Kantor G L, Bickel Y B. Barnett E V. Coexr
lupus erythematosus and rheumatoid arthritis
47: 433-44.
5 Baldwin D S. Lowenstein J. Rothfield
McCluskey R T. The clinical course of the
membranous forms of lupus nephritis. Ann Itit
929-42.
SIR, It is not surprising to see discrepant
occurrence of rheumatoid factors (RF) it
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Methylprednisolone pulse
therapy in rheumatoid arthritis
ematosus (SLE). SIR, The paper entitled 'Combination of methylprednisol-
one pulse therapy and remission inducing drugs in rheuma-
.
Svstemic lupus toid arthritis' published in the Annals' concludes that pulse
vith immunologic therapy is of little or no value in the long term treatment ofJ
rheumatoid arthritis.
stencc of svstemic We believe that there are several deficiencies in this
Ain J Med 196t9 study and that the conclusions are not justified. To justify
such a conclusion the authors must ensure that a type II
N F. Gallo G6 error has not occurred. There is no estimate of the power
proliferative and of their studv, but it is possible to calculate it.2 We estimate
era Med 1970; 73: that their study would not be able to detect a 30(%
difference between the two treatment groups because of
the small numbers in each group. In fact there is a trend in
all their results which favours the active pulse group. This
is further compounded by the fact that three different
results on the remission inducing drugs were used in each treatment
n patients with group, which removes homogeneity of the treatment
thout renal dis- groups and adds another variable to the treatment pro-
isue and noted tocol. Also, although this is claimed to be a double blind
study, the fact that the first assessment was performed one
latin p revo to two weeks after treatment, when the patients receivinglAtteao nforfl() iactive pulse therapy showed significant disease sup-ittheonlsion fof pression, means that the observer could not possiblv be
eults. The main blinded to the treatment the patient had received. As most
RF in patients patients have disease duration of at least two years, during
which time most of the erosive changes are known to
renal disease, a
tudies. occur, it is hardly surprising that x rays taken only eight
months after treatment failed to show any difference
between the two treatment groups. The authors decided to
If HFLIN delete error bars on their figures and not include any
A PASTERNACK- results from immune complex estimations, which makes it
difficult for the reader to assess the results independently.
Finally, no assessment was made at any stage, as to
whether the two treatment groups were identical at the
start of treatment. As a result of these deficiencies we
M KORPFI A believe that this paper has not justified the conclusions that
J MUSTONFN the authors have drawn.
The question of whether initiation of pulse methyl-
prednisolone therapy at the start of treatment with a
remission inducing agent alters the efficacy or side effects
of such an agent remains unanswered.
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SIR, Doctor Smith and his colleagues incorrectly quote
from the abstract of our paper that pulse therapy is of little
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